DCF — HONORHEALTH SONORAN CROSSING MED CTR
Enterprise Value: $-104.7M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-104.7M
Enterprise Value
$-34.2M
PV of Cash Flows
$-70.5M
PV of Terminal Value
$-113.5M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $97.2M | $-5.9M | -6.0% | $-10.1M | $-9.1M |
| Year 2 | $100.2M | $-5.1M | -5.0% | $-9.4M | $-7.7M |
| Year 3 | $103.2M | $-4.2M | -4.0% | $-8.6M | $-6.5M |
| Year 4 | $106.3M | $-3.8M | -4.0% | $-8.3M | $-5.7M |
| Year 5 | $109.4M | $-3.7M | -3.0% | $-8.3M | $-5.2M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-104.7M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$94.4M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.06606516689557455
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5